Updated June 2026
Biohacking for Longevity: What the 2026 Evidence Actually Supports
Somewhere between the $499 ring on your finger and the $50 million trial that was never run sits the actual truth about biohacking: most of what people pay for has never been tested in a human body, and the one tool that has — a $20 hand-grip dynamometer — is sitting unused in a drawer.
A grip dynamometer reading can now predict how long you will live more accurately than your cholesterol panel. That single fact, confirmed across a UK Biobank cohort of roughly half a million people, has quietly upended what doctors consider a vital sign. Most longevity content skips it entirely, because a $20 hand-grip tool is a worse advertisement than a $349 ring.
The longevity market is worth $56.2 billion this year and is growing at a 24.8% annual rate, on pace to reach $134.75 billion by 2030, according to market research aggregated by The Business Research Company. Most of that spending is not going toward the two interventions with the strongest mortality data behind them — cardiorespiratory fitness and muscular strength. It is going toward supplements, rings, and infusions with a thinner evidence base, sold by people who have every incentive to keep the conversation murky.
This article separates the biohacking tools with peer-reviewed mortality data behind them from the ones still waiting on a real trial. It covers what wearables can and cannot measure, what the newest NAD+ research actually found, what a properly designed rapamycin trial would cost, and which popular interventions have already sent people to the emergency room.
- The market versus the evidence
- The two metrics doctors wish you tracked
- What wearables are actually good for
- NAD+ supplements: the 2026 verdict
- Where biohacking turns into a gamble
- Who this is for
- The verdict
The Market Versus the Evidence
Seventy percent of consumers say they intend to increase spending on longevity-focused products this year, according to McKinsey & Company research cited in 2026 industry data. A separate consumer survey found the average self-identified biohacker spends $214 a month, and 82% of them say the cost feels justified, per the Sanctuary Wellness Institute survey reported by Forbes. Supplement use leads the list of methods at 65%, followed by meditation and fasting.
None of that spending data tells you whether the products work. It tells you that the category has crossed from a Silicon Valley curiosity into a mainstream budget line, somewhere between a gym membership and a car payment. The gap between what people buy and what has been tested in a real trial is the entire story of this article.
The Two Metrics Doctors Wish You Tracked
A 2018 Cleveland Clinic analysis of 122,007 patients found that low cardiorespiratory fitness carried a higher mortality risk than smoking, diabetes, or established coronary artery disease, according to the study published in JAMA Network Open and reviewed in subsequent fitness literature. Moving from the bottom 25th percentile of fitness to merely "below average" cut all-cause mortality risk by close to half. Reaching the top tier — "elite" cardiorespiratory fitness — was associated with an 80% reduction in mortality compared with the least fit group.
Grip strength tells a similar story from a different angle. A UK Biobank analysis of roughly half a million adults found grip strength inversely associated with all-cause mortality and with cardiovascular disease, COPD, and several cancers, independent of biochemical screening, according to research published in PMC. A separate longitudinal study of adults over 70 found that a declining grip strength trajectory raised mortality risk by 16% in men and 33% in women per kilogram lost each year, while a rising trajectory cut risk by 31%, regardless of where someone started, per a study in PMC tracking grip strength change in very old adults.
You can test both at home. A dynamometer costs less than a tank of gas. The Cooper 12-minute run test estimates VO2 max for free. Neither requires a subscription, an app, or a ring.
The instruments that predict how long you live the best are the ones the wellness industry has the least financial reason to sell you.
What Wearables Are Actually Good For
Sleep and recovery wearables earned their place by doing one thing reliably: turning a vague feeling of tiredness into a number you can act on. They have not earned a place as longevity oracles, and the pricing tells its own story about what you are actually buying.
| Device | Upfront Cost | Ongoing Cost | 5-Year Total (approx.) |
|---|---|---|---|
| Oura Ring 4 | $299–$349 | $5.99/mo or $69.99/yr | ~$637 |
| Whoop 5.0 (annual plan) | $0 (device included) | $199–$359/yr by tier | $1,195–$1,800 |
| Ultrahuman Ring PRO | ~$349 | None required for core features | ~$349 |
Figures reflect the latest available data at time of writing. Always verify current pricing with official sources.
Oura is the only ring in this category that integrates with a continuous glucose monitor, and only one — Dexcom's Stelo — as of 2026, according to a dual-wear comparison covering both platforms. Whoop bricks entirely without an active membership; cancel and the strap stops reporting anything, per the same review. That is worth knowing before you commit to either ecosystem for years of data continuity.
You have just woken up to a Readiness Score of 61 and a vague sense that something is wrong. The number cannot tell you whether that is poor sleep architecture, dehydration, or a hangover from the wine at dinner. It can tell you to pay attention. That is the actual ceiling of what these devices do — they are attention directors, not diagnosticians.
NAD+ Supplements: The 2026 Verdict
This is where the article's position shifted while researching it. The early assumption going in was that NAD+ precursors belonged in the same bucket as most wellness supplements — plausible biology, no real human data. That turned out to be only half true.
A 2026 PRISMA-guided systematic review screened 113 studies — 33 of them human intervention trials — and found that oral NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) do have a "moderate and growing" human evidence base, according to the review published in Ageing Research Reviews. A Nestlأ© Health Science trial published in Nature Metabolism found that NR and NMN roughly double circulating NAD+ levels within 14 days, while plain nicotinamide only produces a brief four-hour spike, per results reported by NMN.com.
That same 2026 systematic review found something the NAD+ supplement industry rarely mentions on a product page.
No eligible outcomes trial has ever tested IV or IM NAD+ for anti-aging or wellness claims.
The clinics charging hundreds of dollars per infusion are selling a delivery method with zero controlled trial support, while the $30 capsule bottle next to it has actual — if modest — human data. A 28-day randomized, double-blind, placebo-controlled trial of one commercial NAD+ formula reported improved well-being scores, but the study was funded by the supplement's own manufacturer and has not cleared peer review, appearing only on the preprint server medRxiv as of this 2026 posting. No long-term human safety data exists for NR or NMN beyond several months of use, according to a 2026 physician guide reviewing the evidence.
Where Biohacking Turns Into a Gamble
Andrew Steele, an independent longevity researcher in Berlin, put the central problem in five words: no medical intervention has ever been proven to extend human life by targeting aging itself, he told Nature earlier this year. Steele also estimates that a properly powered rapamycin trial in healthy adults would cost $50–100 million — a fraction of the net worth of the people currently dosing themselves with it off-label based on mouse data, per the same reporting, also covered by Scientific American.
Nir Barzilai, president of the Academy for Geroscience, offered a more measured read on the self-experimentation trend: the supplements and drugs popular among high-profile biohackers are usually "based on biology but not on clinical evidence," he said, which is a different category of risk than acting on nothing at all.
The riskier end of the spectrum is not ambiguous. Boston Magazine's 2026 reporting on the city's longevity clinics documented patients buying unregulated peptides like epitalon online, traveling abroad for unapproved gene therapies, and paying for off-label plasma-exchange procedures with no controlled trial behind them, according to the investigation. Emergency physician Matthew Mostofi described treating patients who had taken untested supplements or traveled for unregulated stem cell injections, often with no medical record of what they had actually received. Tim Ferriss and Kevin Rose used their own podcast this year to warn listeners off exogenous ketone supplements containing 1,3-butanediol, after animal data suggested a link to fatty liver injury — a compound that had been marketed for years as a premium cognitive aid before that warning surfaced.
- Rapamycin for longevity has never been tested in a human trial designed to measure lifespan or healthspan outcomes.
- IV NAD+ therapy has zero randomized controlled trial support as of 2026, despite widespread clinical marketing.
- Unregulated peptides purchased online carry no manufacturing oversight and no dosing safety data.
- Off-label plasma exchange for anti-aging purposes has not been validated in controlled human studies.
- 1,3-butanediol, found in some exogenous ketone products, has been linked to liver injury in animal models.
Who This Is For
If you are 45 and your last cardio session was a flight of stairs, the fitness data above is your starting point — a hand-grip test and a 12-minute run will tell you more than any ring on your finger. If you already train consistently and want to close the gap between "feels fine" and "actually recovering," a sleep and HRV wearable earns its subscription. If you are eyeing an NAD+ stack, the oral route has more support behind it than the IV lounge down the street, though "more support" still means modest and short-term. If someone is offering you a peptide that arrived in unmarked packaging or a plasma-exchange appointment at a strip-mall clinic, that is a different category of decision, and it belongs in front of a physician before it belongs in your bloodstream.
A second-time entrepreneur in his late 40s who has read everything Bryan Johnson posts is still, statistically, better served by a dynamometer and a 5K time than by a $499 ceramic ring. The data does not care how the intervention looks on camera.
The Verdict
Spend first on the two things with mortality data behind them: structured cardio training toward a higher VO2 max, and resistance training that protects grip and muscle strength into your 60s and beyond. Spend second on sleep tracking if your recovery habits are genuinely a mystery to you — Oura's pricing model is cheaper over five years than Whoop's, and only Oura currently pairs with a CGM. Treat oral NAD+ precursors as a modest, short-term-tested option, not a verdict on aging itself. Treat IV NAD+, off-label rapamycin, unregulated peptides, and plasma-exchange clinics as experimental medicine you are paying to undergo, not consumer wellness — because right now, that is exactly what they are.
None of this resolves the actual tension underneath the longevity market: the interventions with the strongest data are also the least profitable to sell, and the ones generating the most revenue are the ones still waiting on a trial that may cost more than most of their customers will ever spend combined.
Does biohacking actually make you live longer?
Some of it does. Cardiorespiratory fitness and grip strength both carry strong mortality data behind them in large population studies. Most supplement and device-based biohacks have weaker evidence, ranging from modest human data to none at all.
Is NAD+ IV therapy worth the money in 2026?
No randomized controlled trial has tested IV or IM NAD+ for anti-aging or wellness outcomes as of 2026. Oral NAD+ precursors have more human trial data behind them, though still modest and short-term.
Is Oura Ring or Whoop better for longevity tracking?
Oura is generally cheaper over five years and is currently the only one of the two that integrates with a continuous glucose monitor. Whoop requires an active subscription for the device to function at all, while Oura still provides basic metrics if you cancel.
What is a good VO2 max for my age?
Mortality risk drops sharply once you move out of the bottom quartile of fitness for your age and sex, even without reaching elite levels. A 12-minute Cooper run test or a fitness watch estimate is enough to get a usable baseline.
Is taking rapamycin for longevity safe?
It has never been tested in a human trial designed to measure lifespan or healthspan outcomes. People using it off-label for anti-aging purposes are acting on mouse and biological-plausibility data, not clinical trial results.
How much do people actually spend on biohacking?
Surveyed self-identified biohackers reported average monthly spending of $214, with the large majority saying the cost felt worthwhile, according to a 2025 industry survey.
Are peptides like epitalon legal and safe to buy online?
Most longevity peptides sold direct-to-consumer are not approved for medical use, and physicians have reported treating patients harmed by unregulated versions purchased without oversight.